logo
Plus   Neg
Share
Email

Merck Presents Interim Data From Phase 2a Trial Of Treatment For Pre-exposure Prophylaxis

Merck (MRK) Tuesday announced new interim data from the Phase 2a trial in adults evaluating the safety, tolerability and pharmacokinetics of islatravir, the company's investigational oral nucleoside reverse transcriptase translocation inhibitor, for pre-exposure prophylaxis.

Pre-exposure prophylaxis or PrEP is a way for people who do not have HIV but who are at very high risk of getting HIV to prevent HIV infection by taking a pill every day.

Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied.

In the interim analysis using blinded data, both monthly doses of islatravir were found to have an acceptable tolerability profile.

"These results provide support for further study of islatravir as a once-monthly oral PrEP regimen," said Sharon Hillier, Ph.D., senior investigator at the Magee-Womens Research Institute, and professor of obstetrics, gynecology and reproductive sciences of the University of Pittsburgh, the study's lead investigator. "There is an urgent need for additional, longer acting HIV prevention options to help a wider range of people protect themselves."

In the ongoing Phase 2a trial in adults at low-risk for acquiring HIV-1 infection, participants were randomly assigned to one of three oral once-monthly therapy groups.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example. Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations. Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...
Follow RTT